reason report
initi mp divers portfolio tough gener environ
bottom line strong pipelin gener insulin/
biosimilar off-set continu high single-
digit-bas gener eros support revenu growth
howev well understood view
potenti near-term upsid consensu number could
come limit competit copaxon potenti advair
approv difficult high visibl upsid
estim could come greater-than-expect delay launch
gener gx copaxon multipl sclerosi sandoz advair
asthma copd get approv earlier expect time-frame
also risk-adjust sale probabl success
gener line consensu estim
ep believ meet ep
target strong pipelin growth and/or capit deploy
in-lin consensu sale
consensu ep due share buy-back upsid could
potenti come insulin/biosimilar howev see
meaning sale contributor next month
strong balanc sheet give option capit
deploy hit ep target forecast net
debt/ebitda ratio declin
cash balanc grow despit addit share buy-
back
strong catalyst near term well reflect stock
near term expect see momentum stock continu
drive share gener copaxon potenti obtain
approv advair insulin/biosimilar howev believ
upsid catalyst alreadi reflect stock
current level look improv visibl compani
medium- long-term growth get construct stock
price target base weight averag ev/ebitda
multipl ebitda line consensu
ev/ebitda multipl
net debt total capit
gener
compani inform leerink partner llc research
revenu
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
initi coverag market perform rate pt
divers portfolio tough gener environ
interest pipelin larg reflect stock
current level view
strong pipelin gener insulin/biosimilar
off-set continu high-singl digit
base gener eros support revenu growth
potenti near-term upsid consensu
number limit competit copaxon
advair difficult visibl
line sale
ep mostli due share buyback
balanc sheet give option capit
deploy hit ep
biosimilar growth driver could
expand multipl rel peer
multipl slight expans current
level ebitda line
consensu deriv pt
like fda approv gener advair
like fda approv biosimilar neulasta white
like us launch biosimilar herceptin
breast gastric cancer late
risk invest thesi valuat
gener advair may get approv
limit visibl time new gener
advair approv may drive near-term upsid mostli priced-in look
improv visibl long-term pipelin includ biosimilar
compani report factset leerink partner estim market cap million average volum thousand
vs vs
lead pharmaceut compani across brand gener over-the-counter
found becam public limit liabil compani
netherland
one industri broadest product portfolio
market product countries/territori
significantli expand global over-the-counter footprint
acquisit meda
notabl acquisit includ topic
fami women epd ou specialti brand
gener agila inject
top brand product includ epipen emerg treatment allerg
reaction perforomist long-term treatment copd
rest world
sale primarili oral solid dosag inject transderm patch topic
gel cream ointment unit dose offer
epipen author gener dispens epinephrin auto-injector
oper countri includ lead market share franc itali
netherland
hcv market india therapeut area includ critic care
hepatolog oncolog critic care
lead market share australia new zealand emerg presenc
japan brazil china
compani report leerink partner analysi
downsid
revenu vs consensu in-lin vs
con expect grow compound-annual-growth-rate
gross margin increas
trend back
oper margin improv rang
ep line vs con vs con
expect grow compound-annual-growth-rate
net debt ebitda leverag
gener net debt payment give
ampl flexibl share buy-back hit ep target
fda approv gener advair like
fda approv biosimilar neulasta like like
us launch biosimilar herceptin settl term undisclos
assum late launch
ebitda line consensu
expect current stock level get greater visibl
gener advair approv insulin/biosimilar launch
expect multipl expans
compani report leerink partner estim
past year trade roughli
gener peer
ev/ebitda multipl vs peer
gener index calcul use weight averag roll year forward ev/ebitda multipl
howev stock appreci past month
approach trail high
propos
acquir
propos acquir
propos
acquir meda
fda approv first
gener version
fail acquir
factset leerink partner estim
invest thesi ep achiev difficult
signific upsid insulin/biosimilar pipelin interest earli
differ
total gener sale like flat
gener line consensu
driven
specif follow
gx copaxon sale
gx copaxon exit
market like line con
gx advair sale
partial off-set continu high
gx advair good chanc
approv difficult high
convict time line
con includ risk-adjust sale
believ achiev
con assum ep
bottom-up analysi give us visibl pipelin
could add ep
annual gx copaxon
cost save meda
share buy-back
debt payment think flexibl
even share buy-back reach
ep
see limit near term catalyst
model insulin/biosimilar
longer
drive signific upsid stock
optimist leader
insulin/biosimilar could
space due demonstr success
partner biocon
upsid earn longer term
compani report leerink partner estim
strong year ebit growth driven
copaxon potenti advair gener ep
includ rest na eu row busi
compani report leerink partner estim
potenti avenu upsid
copaxon advair
scenario
gener
addit player
addit gener enter
gener
addit player hikma
get approv
howev scenario well understood
difficult high visibl
risk-adjust estim model
compani report leerink partner estim
manag ep target look achiev
given copaxon approv strong balanc sheet
bridg ep
see ep
achiev
share buy-back
line
assum oper margin line current corpor margin
compani report leerink partner estim
year expect base eros off-set
gx pipelin growth come insulin/biosimilar pipelin
bridg revenu
mylan
pipelin
certain vs
despit compound-annual-growth-rate top-lin growth expect margin remain
gener flat econom insulin/biosimilar pipelin share
assum oper margin line current corpor margin
compani report leerink partner estim
believ greater visibl higher barrier-to-entri
product pipelin drive multipl expans
line current
market view ebitda
impli current
progress
 advair
drive multipl
expans
compani report leerink partner estim
upside/downsid scenario
none
copaxon
advair
gener
rest
compani report factset leerink estim
rank mylan along stock select criteria
criteriadescript mani scaleupside/ downsid leerink revenu ep estim rel consensusw in-lin consensu revenu epsbal sheet flexibility leverag balanc sheet capit deploy base metric chang leverag ratio chang yieldstrong balanc sheet could allow busi develop activ near term catalyst may meaning /- impact stockw see advair key catalyst along biosimilar updat potenti bd developmentsvalu upside/ downsid leerink valuat estim rel stock priceour ev/ebitda analysi point valuat in-lin current level
visibl new
visibl new
could signific
opportun mylan
first market
think approv larg
assum street
estimate
approv
investor like ascrib
credit broader
believ could
least addit
competitor
limit visibl time
competitor near
compani report leerink estim
risk invest thesi
may
potenti downsid risk estim
addit competit exist product includ gx copaxon
continu signific delay advair approv
delay fda approv new product opportun
potenti upsid risk estim
delay fda approv competitor gx product
undisclos pipelin may product estim
higher lower
eros
develop
note
potenti downsid risk estim
potenti consolid buyer industri
exist consortium could continu exert pressur price
potenti upsid risk estim
altern distribut model may benefici manufactur
limit competit exist gx portfolio
potenti downsid risk estim
continu slow uptak biosimilar aggress contract
delay fda/ema approv
manufactur concern biocon plant may result delay
disrupt biosimilar launch/distribut
potenti upsid risk estim
delay competitor biosimilar get fda/ema approv
faster expect improv biosimilar util
compani report leerink estim
year previou role presid chief oper offic
vice presid strateg corpor develop
serv director associ access medicin
serv chairman vice chairman director gener pharmaceut
undergradu degre west virginia univers
held variou leadership posit sinc join
previou posit includ ceo matrix head global develop
regulatori sandoz head gener ranbaxi
master degre pharmaceut technolog punjab univers india
chief offic sinc june year corpor financ
chief offic senior vice presid
previous held variou posit unit technolog
start career public account lybrand becam
bachelor scienc degre account univers tulsa
compani report bloomberg
number except per share data
number except per share data
number except per share data
assum ftf product
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
restasi assum launch pend approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
sale
sale
sale
